FREEDOM: A phase 3b efficacy and safety study of fedrati nib in intermediate- or high-risk myelofibrosis patients previously treated with ruxolitinib.

被引：0
|
作者：
Verstovsek, Srdan
Harrison, Claire N.
Barosi, Giovanni
Kiladjian, Jean-Jacques
Buglio, Daniela
Chia, Vincent
Gerike, Torsten
Jessent-Ciaravino, Valerie
Mostillo, Joseph
Zhang, Jun
Mesa, Ruben A.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Guys & St Thomas NHS Fdn Trust, London, England
[3] IRCCS Policlin San Matteo Fdn, Pavia, Italy
[4] St Louis Hosp, AP HP, Paris, France
[5] Paris Diderot Univ, Paris, France
[6] Celgene Corp, Summit, NJ USA
[7] UT Hlth San Antonio Canc Ctr, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7072
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib
    Gupta, Vikas
    Yacoub, Abdulraheem
    Fazal, Salman
    Miller, Carole
    Verstovsek, Srdan
    Mesa, Ruben
    Harrison, Claire
    Barosi, Giovanni
    Kiladjian, Jean-Jacques
    Mattison, Ryan
    Rein, Lindsay
    Reeves, Brandi
    Oh, Stephen
    Parameswaran, Vinod
    Deeg, Joachim
    Rose, Shelonitda
    Chia, Vincent
    Wang, Tianhua
    Talpaz, Moshe
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S331 - S332
  • [2] A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
    Couban, Stephen
    Benevolo, Giulia
    Donnellan, William
    Cultrera, Jennifer
    Koschmieder, Steffen
    Verstovsek, Srdan
    Hooper, Gregory
    Hertig, Christian
    Tandon, Maneesh
    Dimier, Natalie
    Malhi, Vikram
    Passamonti, Francesco
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [3] A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
    Stephen Couban
    Giulia Benevolo
    William Donnellan
    Jennifer Cultrera
    Steffen Koschmieder
    Srdan Verstovsek
    Gregory Hooper
    Christian Hertig
    Maneesh Tandon
    Natalie Dimier
    Vikram Malhi
    Francesco Passamonti
    [J]. Journal of Hematology & Oncology, 11
  • [4] Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis
    Couban, Stephen
    Benevolo, Giulia
    Donnellan, William
    Cultrera, Jennifer
    Koschmieder, Steffen
    Verstovsek, Srdan
    Hooper, Gregory
    Hertig, Christian
    Tandon, Maneesh
    Dimier, Natalie
    Templeton, Ian
    Passamonti, Francesco
    [J]. BLOOD, 2017, 130
  • [5] Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial
    Gupta, Vikas
    Yacoub, Abdulraheem
    Verstovsek, Srdan
    Mesa, Ruben A.
    Harrison, Claire N.
    Barosi, Giovanni
    Kiladjian, Jean-Jacques
    Deeg, H. Joachim
    Fazal, Salman
    Foltz, Lynda
    Mattison, Ryan J.
    Miller, Carole B.
    Parameswaran, Vinod
    Gharpure, Vishwanath
    Hernandez, Christopher
    Wang, Tianhua
    Talpaz, Moshe
    [J]. BLOOD, 2021, 138
  • [6] Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study
    Harrison, Claire N.
    Mesa, Ruben
    Talpaz, Moshe
    Al-Ali, Haifa Kathrin
    Xicoy, Blanca
    Passamonti, Francesco
    Palandri, Francesca
    Benevolo, Giulia
    Vannucchi, Alessandro M.
    Mediavilla, Clemence
    Iurlo, Alessandra
    Kim, InHo
    Brown, Patrick
    Hernandez, Christopher
    Rose, Shelonitda
    Wang, Jia
    Kiladjian, Jean-Jacques
    [J]. BLOOD, 2023, 142
  • [7] Preliminary gastrointestinal safety and tolerability of fedratinib from the phase IIIb FREEDOM trial in patients with intermediateor high-risk myelofibrosis previously treated with ruxolitinib
    Harrison, Claire
    Gupta, Vikas
    Yacoub, Abdulraheem
    Fazal, Salman
    Miller, Carole
    Verstovsek, Srdan
    Mesa, Ruben
    Barosi, Giovanni
    Kiladjian, Jean-Jacques
    Mattison, Ryan
    Rein, Lindsay
    Reeves, Brandi
    Oh, Stephen
    Parameswaran, Vinod
    Deeg, H. Joachim
    Rose, Shelonitda
    Chia, Vincent
    Wang, Tianhua
    Talpaz, Moshe
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 110 - 111
  • [8] Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial
    Gupta, Vikas
    Yacoub, Abdulraheem
    Mesa, Ruben A.
    Harrison, Claire N.
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Deeg, Hans-Joachim
    Fazal, Salman
    Foltz, Lynda
    Mattison, Ryan J.
    Miller, Carole B.
    Parameswaran, Vinod
    Brown, Patrick
    Hernandez, Christopher
    Wang, Jia
    Talpaz, Moshe
    [J]. LEUKEMIA & LYMPHOMA, 2024, 65 (09) : 1314 - 1324
  • [9] COMPARING THE SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH DIPSS LOW/INTERMEDIATE-1-, INTERMEDIATE-2-, AND HIGH-RISK MYELOFIBROSIS (MF) IN JUMP, A PHASE 3B, EXPANDED-ACCESS STUDY
    Passamonti, F.
    Gupta, V.
    Martino, B.
    Foltz, L.
    Zaritksey, A.
    Al-Ali, H. K.
    Tavares, R.
    Maffioli, M.
    Raanani, P.
    Giraldo, P.
    Griesshammer, M.
    Bouard, C.
    Ronco, J. Perez
    Tiwari, R.
    Vannucchi, A. M.
    [J]. HAEMATOLOGICA, 2017, 102 : 548 - 548
  • [10] Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis
    Kiladjian, Jean-Jacques
    Heidel, Florian H.
    Vannucchi, Alessandro M.
    Ribrag, Vincent
    Passamonti, Francesco
    Hayat, Amjad
    Conneally, Eibhlin
    Martino, Bruno
    Kindler, Thomas
    Lipka, Daniel B.
    Acharyya, Suddhasatta
    Gopalakrishna, Prashanth
    Ide, Susan E.
    Loechner, Sabine
    Mu, Song
    Harrison, Claire N.
    [J]. BLOOD, 2014, 124 (21)
12345